l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial

What Was Tested

The paper reports a study of Carnosine, published as a randomized controlled trial.

Considering the pathologic importance of metabolic disturbances, advanced glycation end products (AGEs), and chronic inflammation in diabetes mellitus and ameliorating potentials of l-carnosine in hampering these detritions and because these effects have not been investigated in patients with type 2 diabetes (T2D) so far, the researchers conducted the current study.

Who Took Part

According to the abstract, 54 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Carnosine and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Carnosine, so expectations could not easily colour the readings.

Some patients received a placebo instead of Carnosine, giving a reference point.

The methods mention a period of 12 weeks.

What Was Measured

Topics PubMed links to this paper include Adipose Tissue, Arginine, Blood Glucose, Body Composition, Carnosine, Diabetes Mellitus, Type 2 and Dietary Supplements.

The authors tagged it with the keywords Age, Glycemic status, Inflammation, Lipid profile, Type 2 diabetes mellitus and l-Carnosine.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Carnosine in 54 patients over 12 weeks.

The publication is from 2018 (Nutrition research (New York, N.Y.)), a journal based in United States.

More context: the Carnosine compound page, all human trials.